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Introduction. Trefoil factor family (TFF) peptides are increased in serum and urine in patients with chronic kidney disease (CKD).
However, whether the levels of TFFpredict the progression ofCKDremains to be elucidated.Methods.Wedetermined theTFF levels
using peptide-specific ELISA in spot urine samples and performed a prospective cohort study. The association between the levels
of urine TFFs and other urine biomarkers as well as the renal prognosis was analyzed in 216 CKD patients (mean age: 53.7 years,
47.7% female, 56.9% with chronic glomerulonephritis, and mean eGFR: 58.5ml/min/1.73m2). Results. The urine TFF1 and TFF3
levels significantly increased with the progression of CKD stages, but not the urine TFF2 levels. The TFF1 and TFF3 peptide levels
predicted the progression of CKD ≥ stage 3b by ROC analysis (AUC 0.750 and 0.879, resp.); however, TFF3 alone predicted CKD
progression in a multivariate logistic regression analysis (odds ratio 3.854, 95% confidence interval 1.316–11.55). The Kaplan-Meier
survival curves demonstrated that patients with a higher TFF1 and TFF3 alone, or in combination with macroalbuminuria, had a
significantly worse renal prognosis. Conclusion. The data suggested that urine TFF peptides are associated with renal progression
and the outcomes in patients with CKD.
1. Introduction
Chronic kidney disease (CKD) is defined as having either
glomerular filtration rate (GFR) < 60mL/min/1.73m2 or
markers of kidney damage for at least 3 months or both
[1, 2]. CKD with multifactorial etiology leading to end-
stage renal disease (ESRD) is a significant concern, given
the increasing numbers of such patients worldwide [3]. CKD
is not only associated with an elevated risk of ESRD but
also with cardiovascular disease and mortality, even with a
slight decline in the GFR [4, 5]. A lower estimated GFR
(eGFR) and severe albuminuria independently predict ESRD
and mortality in patients with CKD [6]. Several reports have
identified and validated novel biomarkers in CKD patients in
order to better identify those at high risk of a rapid loss of the
renal function [7].
The mammalian trefoil factor family (TFF) peptides
consist of a three-looped structure of cysteine residues,
known as the trefoil domain, and the family comprises three
members in mammals: TFF1, TFF2, and TFF3 [8, 9]. TFF1
and TFF3 contain one trefoil domain, while TFF2 contains
two. TFF1 and TFF3 can dimerize to homodimers through
a seventh cysteine residue [10]. These small peptides, with
a molecular weight of approximately 7 kDa, are secreted by
mucus-producing cells in the gastrointestinal tract and are
involved in mucosal surface maintenance and repair [11, 12].
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They are also secreted by epithelial cells of multiple tissues,
including tubular epithelial cells of kidney [13], through a
seventh cysteine residue located near the C-terminus.
In the human urinary tract, TFF3 is detected as the most
abundant form followed by TFF1 [14]. In rodent models,
urine TFF3 markedly reduced after acute renal toxicity [15],
and it has already been proposed as a urine biomarker for
kidney toxicity in preclinical stages [16]. Higher urine levels
of TFF3 were shown to be associated with incident CKD
in community-based populations [17]; however, they were
not associated with incident CKD or albuminuria in another
prospective cohort of Framingham Heart Study participants
[18]. In recent studies in patients with CKD, increased levels
of urine TFF1 [19] and urine TFF2 [20] have been reported in
early CKD stages, whereas urine TFF3 levels are increased in
later CKD stages [19, 21].
Given the above conflicting findings, whether or not urine
TFF levels can be used to predict the renal outcome is still
uncertain in patients with CKD. We therefore examined the
urine levels of TFF and investigated the relationship between
urine TFF and the renal progression and outcomes in patients
with CKD.
2. Material and Methods
2.1. Subjects. The subjects in this study were outpatients who
had visited the Renal Unit of Okayama University Hospi-
tal between February 2009 and January 2011. All patients
were diagnosed with CKD according to their eGFR and
the presence of kidney injury, as defined by the National
Kidney Foundation K/DOQI Guideline [22]. Hypertension
was defined as systolic blood pressure (SBP) ≥ 140mmHg
or diastolic blood pressure (DBP) ≥ 90mmHg or the use of
antihypertensive drugs. The eGFR was calculated according
to the simplified version of the Modification of Diet in
Renal Disease formula [eGFR = 194 × (sCr)−1.094 × (age)−0.287
(if female × 0.739)] [23]. All procedures in the present
study were carried out in accordance with institutional and
national ethical guidelines for human studies and guidelines
proposed in the Declaration of Helsinki. The ethics com-
mittee of Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences approved the study
(number 522 and revision number 2063). Written informed
consent was obtained from each subject. This study was
registered with the Clinical Trial Registry of the University
Hospital Medical Information Network (registration number
UMIN000010140).
According to the protocol, we excluded any patients with
established atherosclerotic complications (coronary artery
disease, congestive heart failure, or peripheral vascular dis-
ease). Patients with nephrotic syndrome, acute kidney injury,
acute infection, and malignancy including gastric cancer [24,
25], active gastrointestinal diseases including gastroenteritis
and peptic ulcers, or liver cirrhosis [26] at entry were
excluded (Supplementary Figure S1).
2.2. Study Samples. All urine samples were obtained from
patients from spot urine in the morning [27]. Samples were
spun at 2,000𝑔 for 5 minutes in a refrigerated centrifuge, and
the supernatants were immediately transferred to new screw-
top cryovial tubes and frozen at −80∘C. All urine aliquots
used in this biomarker study had undergone no previous
freeze-thaw cycle. Samples for this study were obtained from
216 participants who were free of ESRD at the time of urine
collection.
2.3. Biomarker Measurements and Other Clinical Param-
eters. The mean storage duration between collection and
measurement was a median of 29 months (interquartile
range, 28–31 months). The TFF peptide (TFF1, TFF2, and
TFF3) concentrations weremeasured using an ELISA system,
as described previously [24, 25]. Antisera were prepared
from rabbits immunized with human TFFs. Purified poly-
clonal antibodies (TFF1: OP-22203, TFF2: OP-20602, and
TFF3: OPP-22303) were coated onto a 96-well microtiter
plate, and the plates were blocked with 0.1% bovine serum
albumin/phosphate-buffered saline (PBS). After the block-
ing solution was removed, 100 𝜇L of assay buffer (1mol/L
NaCl/0.1% bovine serum albumin/PBS) and 50 𝜇L of sample
or human TFF standard were added to the wells. After
incubation overnight at room temperature, the plate was
washed, and diluted biotin-labeled anti-TFF polyclonal anti-
bodies (TFF1: biotin-OPP22205, TFF2: biotin-OPP20601,
and TFF3: biotin-OPP22305) were added to each well.
After incubation for 2 h, the plate was washed, and diluted
horseradish peroxidase-conjugated streptavidin (Vector Lab-
oratories, Burlingame, CA, USA) was added to each well,
followed by a further 2 h incubation at room temperature,
after which the plate was washed. Tetramethylbenzidine
(TMB) solution (Scytek Laboratories, Inc., West Logan, UT,
USA) was then added, stop solution (Scytek Laboratories,
Inc.) was added 10min later, and the absorbance at 450 nm
wasmeasured. Concentrations of humanTFFs in the samples
were calculated from a standard curve constructed from
recombinant human TFFs. The assay sensitivities for TFF1,
TFF2, and TFF3 were 7, 30, and 30 pg/mL, respectively.
Each TFF antibody reacted specifically and showed no cross-
reactivity for the other TFFs [24, 25]. The performance
characteristics of the ELISA are shown in Supplementary
Table S1 and Supplementary Figure S2.
The concentrations of clinical parameters were measured
using routine laboratory methods (SRL, Inc., Okayama,
Japan). The urinary levels of albumin, 𝛼1-microglobulin (𝛼1-
MG), 𝛽2-microglobulin (𝛽2-MG), and N-acetyl-𝛽-D- glu-
cosaminidase (NAG) were also determined (SRL, Inc.). The
serum and urinary creatinine levels weremeasured according
to the enzymatic colorimetric method. Each subject’s arterial
blood pressure wasmeasured by a physician after a 10-minute
resting period to obtain the systolic and diastolic blood
pressures (SBP and DBP, resp.). The mean blood pressure
(MBP) was calculated as DBP + (SBP − DBP)/3 [28].
2.4. Outcomes and Follow-Up. The primary outcome was
CKD progression, defined as a composite endpoint of inci-
dent ESRD (recipient ofmaintenance dialysis or kidney trans-
plant) or doubling of serum creatinine [29]. Patients were
prospectively followed up for a median period of 1097 days
(interquartile range, 794–1244 days). Patients were followed
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Figure 1: Box and line plots showing the levels of urine TFF according to the CKD stages. The levels of both urine TFF1 (𝜇g/gCr) (a) and
TFF3 (𝜇g/gCr) (c) increased along with advancement of CKD stages, while those of urine TFF2 (𝜇g/gCr) did not (b). ∗ and ∗∗ indicate 𝑝 <
0.005 and 𝑝 < 0.0001, respectively. The boxes denote the medians and 25th and 75th percentiles. The lines mark the 5th and 95th percentiles.
by review of themedical record or telephone interview at least
twice a year until March 31, 2013. Death and loss to follow-up
were considered censoring events.
2.5. Statistical Analyses. Statistical analyses were performed
using the JMP software package (release 11; SAS Institute,
Cary, NC, USA). Data are expressed as the mean ± stan-
dard deviation for continuous parametric data, median and
interquartile range for continuous nonparametric data, and
frequencies for categorical data. A linear regression analysis
of the data at baseline was performed using the least-squares
method. Variables showing a positively skewed distribution
were transformed using the natural logarithm (ln). Dif-
ferences between groups were analyzed using Student’s t-
test and the Mann–Whitney 𝑈 test as appropriate. Receiver
operating characteristic (ROC) curves were constructed
to determine the optimum sensitivity and specificity, and
the area under the curve (AUC) was calculated [30]. A
multivariable logistic regression analysis was performed to
determine the predictors [28]. The 𝑝 values, odds ratios, and
corresponding two-sided 95% confidence intervals for the
predictors are presented [31]. A Kaplan-Meier analysis and
the log-rank statistic were used to explore the effect of urine
biomarker levels on the renal endpoint-free survival [29, 31].
Renal survival times were censored only when patients died,
underwent maintenance dialysis or kidney transplantation,
were lost to follow-up monitoring, or completed the study.
The renal survival was calculated from the date of urine
sample collection. A value of 𝑝 < 0.05 was considered to be
statistically significant.
3. Results
3.1. Urine TFF Levels in Early, Middle, and Later CKD
Stages. A total of 216 CKD patients with a mean age of 53.7
years were included in the study (Table 1). More than half
of background causes of CKD included glomerulonephritis
(56.9%). The median urine TFF1, TFF2, and TFF3 levels
were 16.6, 199.7, and 65.3 𝜇g/gCr, respectively. The baseline
characteristics are shown according to early (stages 1 and
2), middle (stages 3a and 3b), and later (stages 4 and 5)
CKD stages (Table 1). Of note, the concentrations of both
urine TFF1 and TFF3 significantly increasedwith progression
of CKD stages; however, those of urine TFF2 did not
(Figure 1). Concentrations of other urine markers of tubular
injury, including 𝛼1-MG, 𝛽2-MG, and NAG, also increased
with CKD progression (Table 1). Regarding the relationships
among urine TFF peptides and other tubular injury markers,
TFF3 correlated well with 𝛼1-MG, 𝛽2-MG, and NAG, and
TFF1 correlated well with 𝛼1-MG and 𝛽2-MG, but TFF2 did
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Table 2: Univariate correlation among uTFF1, uTFF2, uTFF3, and other parameters.
uTFF1 (𝜇g/gCr)
𝑅 value
uTFF2 (𝜇g/gCr)
𝑅 value
uTFF3 (𝜇g/gCr)
𝑅 value
UAE (mg/gCr) 0.1919 −0.0945 0.2143
eGFR (mL/min/1.73m2) −0.3302∗ 0.1126 −0.5016∗
uTFF1 (𝜇g/gCr) — 0.3910∗ 0.4113∗
uTFF2 (𝜇g/gCr) 0.3910∗ — −0.0109
uTFF3 (𝜇g/gCr) 0.4113∗ −0.0109 —
u𝛼1-MG (mg/gCr) 0.4606∗ −0.0378 0.7032∗
u𝛽2-MG (𝜇g/gCr) 0.4021∗ −0.0831 0.5634∗
uNAG (U/gCr) 0.1920 0.1650 0.2709∗
eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; u𝛼1-MG, urinary 𝛼1-microglobulin; u𝛽2-MG, urinary 𝛽2-microglobulin; uNAG,
urinary N-acetyl-𝛽-D-glucosaminidase; uTFF, urinary trefoil factor; ∗𝑝 <0.0001.
not exhibit significant correlations with any of these markers
(Table 2). The associations among mutual TFF peptides in
urine were significant except for those between TFF2 and
TFF3. The correlations between urine TFF peptides and age
were significant (Supplementary Table S2). The data of urine
TFF levels in healthy subjects is also shown in Supplementary
Table S3.
3.2. Predictors of CKD Progression ≥ 3b (eGFR < 45mL/min/
1.73m2) in Urine Biomarkers. The parameter with the largest
area under the ROC curve (AUC) for predicting the pro-
gression of CKD ≥ 3b was urine TFF3 (0.879), followed by
urine 𝛼1-MG (0.874) (Table 3). Regarding the other urine
biomarkers, the AUCs of 𝛽2-MG, TFF1, albumin, and NAG
were also significant. Serum factors such as hemoglobin and
uric acid were significant as well for predicting the CKD
progression, as expected in a typical CKD cohort (Supple-
mentary Table S4). In an analysis with the ratio of urine TFF3
to other parameters, the AUC of the ratio of urine TFF3 to
urine TFF2 was the largest (0.859) (Supplementary Table S5).
In a multivariate logistic regression analysis, higher levels of
urine TFF3 (more than the median value, 65.3 𝜇g/gCr) and
urine 𝛼1-MG (more than the median value, 3.81mg/gCr) at
the start of the study were significantly associated with the
CKD progression (Table 4).
3.3. Prediction of the Renal Survival by Urine TFF. To investi-
gate whether or not the baseline urine TFF levels predict the
subsequent renal survival in CKD patients, we categorized
the patients into groups by the level of each TFF (median
value, 𝜇g/gCr) or in their combination with albuminuria
(<300 or ≥300mg/gCr) in Kaplan-Meier survival analyses
(Figure 2). We observed a significant difference in the three-
year renal endpoint-free survival when patients were divided
into groups according to the median value of urine TFF1 or
TFF3 (Figure 2(a) or 2(c)). In contrast, we observed no signif-
icant difference in the three-year renal survival when patients
were divided into groups by the median value of urine TFF2
(Figure 2(b)). Combining urine TFFs, which are suspected
tubular injury markers, with albuminuria, which mainly
Table 3: AUC for predicting the progression of CKD ≥ 3b.
AUC
Urine biomarkers
uTFF1 (𝜇g/gCr) 0.750∗
uTFF2 (𝜇g/gCr) 0.513
uTFF3 (𝜇g/gCr) 0.879∗
u𝛼1-MG (mg/gCr) 0.874∗
u𝛽2-MG (𝜇g/gCr) 0.800∗
uNAG (U/gCr) 0.674∗
UAE (mg/gCr) 0.692∗
AUC, area under the curve; CKD, chronic kidney disease; UAE, urinary
albumin excretion, u𝛼1-MG, urinary 𝛼1-microglobulin; u𝛽2-MG, urinary
𝛽2-microglobulin; uNAG, urinary N-acetyl-𝛽-D-glucosaminidase; uTFF,
urinary trefoil factor; ∗𝑝 < 0.005.
Table 4: A multiple logistic regression analysis of the predictors of
CKD ≥ 3b.
Odds ratio 95% CI
Urine biomarkers
uTFF1 >median (𝜇g/gCr) 2.221 0.804–6.364
uTFF2 >median (𝜇g/gCr) 1.188 0.474–3.003
uTFF3 >median (𝜇g/gCr) 3.854∗ 1.316–11.55
u𝛼1-MG >median (mg/gCr) 3.958∗ 1.172–14.28
u𝛽2-MG >median (𝜇g/gCr) 1.010 0.380–3.013
uNAG >median (U/gCr) 0.862 0.324–2.172
UAE > 300 (mg/gCr) 1.690 0.674–4.276
Adjusted for age, gender, mean blood pressure, uric acid, and renin
angiotensin system blockade treatment; CI, confidence interval; CKD,
chronic kidney disease; UAE, urinary albumin excretion, u𝛼1-MG, urinary
𝛼1-microglobulin; u𝛽2-MG, urinary 𝛽2-microglobulin; uNAG, urinary N-
acetyl-𝛽-D-glucosaminidase; uTFF, urinary trefoil factor; ∗𝑝 < 0.05.
reflects glomerular injury, the three-year renal endpoint-
free survival probabilities were 100.0% (d), 87.3% (e), and
100.0% (f) for lower TFF1, TFF2, and TFF3 levels (less than
the median value) and lower albuminuria (<300mg/gCr);
78.7% (d), 67.2% (e), and 81.7% (f) for higher albuminuria
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Figure 2: The renal survival categorized by TFF alone (a–c) or by their combination with albuminuria (d–f). The median value of urine
TFF1 (𝜇g/gCr) (a) or TFF3 (𝜇g/gCr) (c) predicted the three-year renal endpoint-free survival, while urine TFF2 (𝜇g/gCr) did not (b). The
combination of urine TFF1 (d) or TFF3 (f) with albuminuria clearly separated the three-year renal endpoint-free survival of CKD patients,
while that of urine TFF2 with albuminuria had a less obvious effect (e). (d) uTFF1/Cr < 16.6 and UAE < 300, 𝑛 = 89 (41.2%), uTFF1/Cr ≥
16.6 or UAE ≥ 300, 𝑛 = 93 (43.1%), uTFF1/Cr ≥ 16.6 and UAE ≥ 300, 𝑛 = 34 (15.7%). (e) uTFF2/Cr < 199.7 and UAE < 300, 𝑛 = 78 (36.1%),
uTFF2/Cr ≥ 199.7 or UAE ≥ 300, 𝑛 = 113 (52.3%), uTFF2/Cr ≥ 199.7 and UAE ≥ 300, 𝑛 = 25 (11.6%). (f) uTFF3/Cr < 65.3 and UAE < 300, 𝑛 =
95 (44.0%), uTFF3/Cr ≥ 65.3 or UAE ≥ 300, 𝑛 = 81 (37.5%), uTFF3/Cr ≥ 65.3 and UAE ≥ 300, 𝑛 = 40 (18.5%). ∗ and ∗∗ indicate 𝑝 < 0.01 and
𝑝 < 0.0001, respectively. UAE, urinary albumin excretion (mg/gCr).
(≥300mg/gCr) alone or higher TFF1, TFF2, or TFF3 alone;
and 51.8% (d), 54.0% (e), and 53.4% (f) for both higher
albuminuria and higher TFF1, TFF2, or TFF3 levels (Figures
2(d)–2(f)). During the 36 months of follow-up, 22 patients
exhibited doubling of serum creatinine (𝑛 = 14) or ESRD
requiring renal replacement therapy (𝑛 = 8). Compared with
the remaining 190 patients (the renal survival group), the
renal endpoint group had significantly higher levels of urine
TFF1 and TFF3 but significantly lower levels of urine TFF2
(Figure 3).
The analyses without creatinine correction of the levels of
urine TFF according to the CKD stages, for the renal survival
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Figure 3: The levels of urine TFF for the renal endpoint group and the renal survival group. The renal endpoint group (right box and line
plot) had higher levels of urine TFF1 (a) and TFF3 (c) but lower levels of urine TFF2 than the renal survival group (b). ∗, ∗∗, and ∗∗∗ indicate
𝑝 < 0.05, 𝑝 < 0.001, and 𝑝 < 0.0001, respectively. The boxes denote the medians and 25th and 75th percentiles. The lines mark the 5th and
95th percentiles.
and for the renal endpoint group or the renal survival group,
are shown in Supplementary Figures S3, S4, and S5, respec-
tively.
4. Discussion
In this study, we measured the urine TFF levels in early,
middle, and later CKD patients and determined the relation-
ships between the urine TFF level and the CKD progression
and outcomes. Based on analyses of urine samples from
CKD patients, we found that (1) the TFF1 and TFF3 levels
significantly increased with progression of CKD stages, while
TFF2 did not; (2) TFF3 to a better degree and TFF1 to a
lesser degree correlated with the decline in the eGFR and
other urine markers of tubular injury, including 𝛼1-MG and
𝛽2-MG, as well as other family peptides TFF1 and TFF3,
respectively; (3) TFF1 and TFF3 were significant predictors of
the progression of CKD ≥ 3b in an ROC analysis, and TFF3
alone, but not TFF1 or TFF2, was a significant predictor in
a multiple logistic regression analysis; and (4) in a survival
analysis, TFF1 and TFF3 either alone or in combination with
the level of albuminuria were a significant predictor of the
renal outcome in patients with CKD.
We showed that the urine levels of both TFF1 and TFF3
significantly increased with the progression of CKD, while
the urine levels of TFF2 did not (Figure 1). Regarding urine
TFF3, Du et al. reported findings consistent with our own
on urine TFF3 in CKD patients [21]. However, as for urine
TFF1, Lebherz-Eichinger et al. reported that urine TFF1 levels
increased in the early stages ofCKDanddeclinedwith disease
progression without significant changes in the fractional
excretion of TFF1 [19], which is inconsistent with our data
on urine TFF1. TFF2 was the first TFF to be identified and
characterized [8, 9]. In the human urinary tract, TFF3 is
detected as the most abundant form followed by TFF1 [14],
while urine TFF2 and TFF3 are increased in patients with
nephrolithiasis [14]. A recent study evaluated the urine TFF2
levels in patients with CKD [20]. Urine TFF2 concentrations
were significantly higher in early or middle CKD stages
than in later CKD stages and predicted early CKD stages
in an ROC analysis, but without significant changes in the
fractional excretion of TFF2 amongCKD stages [20], which is
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also inconsistentwith our data on urineTFF2. Further studies
will be required to clarify these inconsistencies in data on
urine TFF1 and TFF2 levels at different CKD stages.
The origin of urine TFF peptides has yet to be fully eluci-
dated. TFF3 mRNA is expressed in the cortex of the human
kidney [14], in contrast to genes that encode other TFF
members. Elevated levels of TFF3 were also found in urine
from patients with incident chronic kidney disease as part of
a nested case-control study [17], as well as in serumof patients
with CKD stages 1–5 [19, 21]. Cultured human proximal
tubular epithelial cell line HK-2 can synthesize and excrete
TFF3 after exposure to immunoglobulin𝜆 light chain, but not
after exposure to fatty acid-free human serum albumin [32].
The promotor region of human TFF3 has the STAT3 binding
site critical for the self-induction of TFF3 [33] as well as the
NF-𝜅B binding site [34]. Possible triggers for the increase
in TFF3, at least in part, may include inflammation via the
transcription factors STAT3 and NF-𝜅B, both of which are
proposed as central regulators of CKD progression [35, 36].
The exact role of TFF in the kidney is still uncertain.
TFF3, also known as intestinal trefoil factor (ITF), a peptide
expressed in goblet cells of the intestines, colon, and kidney
[37], plays essential functions in both mucosal surface main-
tenance and repair [12]. By inhibiting apoptosis and promot-
ing the survival and migration of epithelial cells into lesions,
TFF3 facilitates the restoration of intestinal epithelium as a
protective barrier against injury [38, 39]. TFF3 also plays a
role in inducing airway epithelial ciliated cell differentiation
[40]. Systemic TFF3 KO mice developed normally and were
grossly indistinguishable from their wild-type littermates
without apparent renal abnormalities but exhibited poor
epithelial regeneration of mucosa after intestinal injury [41].
TFF3 might play a role in the repair of tubular epithelium
in kidney, similar to its role in the gastrointestinal tract.
Examining conditional knockout mice of TFF3 specific to
renal tubular epithelial cells may help clarify the precise
function of TFF3 in the kidney.
The kidney tubules of the outer stripe of the outermedulla
are a major site of tff3 mRNA expression in rodents [15].
Histochemical localization using a labeled TFF3 fusion pro-
tein detected binding sites in the collecting ducts of the
kidney [42], and aging was correlated with a decreased
renal expression of tff3 transcript in rodents [43]. In the
normal human kidney, TFF3 has been found in proximal
and single distal tubular cells as well as in collecting duct
cells from which a small amount of TFF1 is also secreted by
immunohistochemistry, while only TFF3 is detectable by a
Western blot analysis in the medulla [14]. In the collecting
ducts of the medulla, TFF1 and TFF3 are constituents of the
mucus layer [14]. These reports suggest that the increases in
the TFF3 and TFF1 in urine reflect their excretion from the
urinary tract of CKD patients, not merely their leakage from
serum.
The renal distribution of TFF3 protein in CKD patients is
very scant. Immunohistochemistry of renal biopsy specimens
showed aberrant expression of TFF3, which was localized
to the tubular epithelial cells in the renal cortex but not
to the glomeruli, arterioles, or interstitium [21]. The recent
genome-wide association study in the Framingham Heart
Study revealed an association between TFF3 and LRP2
with multiple variants independently associated with urinary
TFF3 levels [44]. Since lrp2 encodes megalin, a multiligand
endocytic receptor localized in the renal proximal tubule,
TFF3 might be a megalin ligand, such like 𝛼1-MG or 𝛽2-
MG [45], leading to altered tubular handling of TFF3 in
the presence of the variants. In acute kidney injury (AKI)
of animal models, a decrease in both urine TFF3 levels and
renal TFF3 staining was observed in nephrotoxin-treated
rodents [15], suggesting a gene regulatory response of TFF3
to tubular toxicity in this setting. In AKI of patients with
acute decompensation of liver cirrhosis, urine TFF3 levels are
significantly increased, particularly in acute tubular necrosis,
compared to patients without AKI [26].
In the survival analysis of this study, TFF1 andTFF3 either
alone or in combination with the level of albuminuria were
found to be a significant predictor for the disease progression
and renal outcome in patients with CKD (Figure 2). In
an analysis of a panel of 14 urine biomarkers for incident
kidney disease and the clinical outcome in the Framingham
Heart Study participants, urine TFF3 levels predicted the
all-cause mortality and death with coexistent kidney disease
but not with incident CKD or albuminuria, although it did
not investigate the renal outcome of doubling of the serum
creatinine level or incident ESRD [18].
The ROC analysis of this study showed that urine TFF3
was a useful biomarker for predicting the progression of
CKD ≥ 3b. Although other biomarkers, such as urine 𝛼1-
MG, urine 𝛽2-MG, and hemoglobin, were also shown to
be good predictors (Table 3 and Table S4), the AUC of
urine TFF3 was the largest among these biomarkers, and the
invasiveness of its measurement is lower than those of other
serum biomarkers. These findings underscore the usefulness
of measuring the urine TFF3 levels.
Our study has several limitations and strengths that
should be kept in mind when interpreting the results. First,
we lacked enough data in patients with diabetic nephropathy,
which was themost frequent cause of ESRD inmodern coun-
tries. However, including diabetic patients in the CKD cohort
might have influenced the TFF levels, as other biomarkers
such as serum Klotho are lower in diabetic patients than
in nondiabetic patients [46]. Second, several methods for
measuring the TFF levels have been established using in-
house ELISA assays, such as in this study and others [21],
or are commercially available in ELISA kits [19] or bead
immunoassay platforms [17, 18]. Previously published data
have reported TFF3 concentrations in the urine of normal
and diseased individuals to span the range between 0.03 and
7.0 𝜇g/mL [47, 48]. The validation of the TFF assay will be
of great importance in the near future such as a paper-based
assaywhich can be quickly and inexpensively performed [48].
Third, relatively few patients reached the outcome, which
might have influenced the results of this study to some extent.
Fourth, the precise expression of TFF in the kidney tissue
of patients with CKD was not investigated in this study,
although a previous report showed localization of TFF3 in
the renal tubular epithelial cells, but not in the glomeruli,
arterioles, or interstitium in renal biopsy specimens of 23
patients with CKD [21].
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5. Conclusions
Our data showed that urine TFF peptides are associated with
other urine tubular injury markers and the renal outcomes in
patients with CKD. Further studies are required to elucidate
the precise localization and function of TFF in the human
kidney and its role in the progression in CKD patients.
Interventions that canmodulate the level of urine TFF in such
patients may be useful, since improving the outcome is the
ultimate goal of biomarker studies.
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